PharmTech Drug Digest 11.20
News|Articles|September 16, 2015

Acquisition Combines Lab Glassware Suppliers Wheaton and Duran Group

The Duran Group’s acquisition of Wheaton combine two brands of laboratory consumables.

Wheaton, a Millville, NJ-based provider of laboratory glassware and consumables, announced on Sept. 15, 2015, that it has been acquired by Duran Group, a portfolio company of funds advised by One Equity Partners Capital Advisors L.P. (OEP) that manufactures specialty glass solutions for the laboratory and industrial glass markets.

The combined company will benefit from a broader base from which to grow their portfolio of products, according to a press statement announcing the merger. Wheaton provides glass and plasticware in North America; Duran provides laboratory glassware in Europe. Both companies also serve Asia and other global markets.

“This acquisition represents a new chapter for Wheaton and will allow us to accelerate a number of growth programs already in progress. Joining a company with the expertise and capabilities of Duran Group additionally opens up many possibilities for improvements and growth,” said Wayne Brinster, president and CEO of Wheaton. “In the areas of products, infrastructure, talent and focus, the two organizations complement each other very well.”

OEP has managed approximately $11 billion in total investments and committed capital for JPMorgan Chase & Co. since 2001.

Source: Wheaton


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.